Publications by authors named "Mark Forrest Gordon"

Claim this Profile
T
Trajectories of Pontine Volume in Patients with Multiple System Atrophy.
Kazuya Kawabata, Florian Krismer, Mizuki Ito, Kazuhiro Hara, Epifanio Bagarinao, Mark Forrest Gordon

Mov Disord· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease.
Samuel Frank, Claudia M Testa, Jody Goldstein, Elise Kayson, Blair R Leavitt, Mark Forrest Gordon

CNS Drugs· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
Samuel Frank, Karen E Anderson, Hubert H Fernandez, Robert A Hauser, Daniel O Claassen, Mark Forrest Gordon

Neurol Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
Samuel Frank, Karen E Anderson, Hubert H Fernandez, Robert A Hauser, Daniel O Claassen, Mark Forrest Gordon

Neurol Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.
Robert A Hauser, Hadas Barkay, Hubert H Fernandez, Joohi Jimenez-Shahed, Stewart A Factor, Mark Forrest Gordon

J Clin Psychopharmacol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Bioequivalence Comparison Between the Once-Daily Extended-Release Tablet and the Twice-Daily Tablet Formulations of Deutetrabenazine at Steady State.
Eva-Maria Sunzel, Laura Rabinovich-Guilatt, Malini Iyengar, Debra Ruffo, Nagnath G Birajdar, Mark Forrest Gordon

Clin Pharmacol Drug Dev· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Ralf Reilmann, Karen E Anderson, Andrew Feigin, Sarah J Tabrizi, Blair R Leavitt, Mark Forrest Gordon

Lancet Neurol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progressive Brain Atrophy in Multiple System Atrophy: A Longitudinal, Multicenter, Magnetic Resonance Imaging Study.
Florian Krismer, Patrice Péran, Vincent Beliveau, Klaus Seppi, Germain Arribarat, Mark Forrest Gordon

Mov Disord· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is the association between blood pressure and cognition in the oldest-old modified by physical, vascular or brain pathology markers? The EMIF-AD 90 + Study.
Nienke Legdeur, Justine E Moonen, Maryam Badissi, Carole H Sudre, Wiesje Pelkmans, Mark Forrest Gordon

BMC Geriatr· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Long-Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open-Label Extension Study.
Joseph Jankovic, Barbara Coffey, Daniel O Claassen, Joohi Jimenez-Shahed, Barry J Gertz, Mark Forrest Gordon

Mov Disord Clin Pract· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Content Validation of the Movement Disorder-Childhood Rating Scale (MD-CRS) for Dyskinetic Cerebral Palsy.
Daniel O Claassen, Heather R Riordan, Leon S Dure, Roberta Battini, Alma Cortez, Mark Forrest Gordon

Pediatr Neurol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A PET-CT study on neuroinflammation in Huntington's disease patients participating in a randomized trial with laquinimod.
Andreas-Antonios Roussakis, Marta Gennaro, Mark Forrest Gordon, Ralf Reilmann, Beth Borowsky

Brain Commun· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration-QTc Analysis.
Frank Schneider, Borje Darpo, Pippa S Loupe, Hongqi Xue, Helena Knebel, Mark Forrest Gordon

Clin Pharmacol Drug Dev· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.
Samuel Frank, Claudia Testa, Mary C Edmondson, Jody Goldstein, Elise Kayson, Mark Forrest Gordon

CNS Drugs· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Connecting real-world digital mobility assessment to clinical outcomes for regulatory and clinical endorsement-the Mobilise-D study protocol.
A Stefanie Mikolaizak, Lynn Rochester, Walter Maetzler, Basil Sharrack, Heleen Demeyer, Mark Forrest Gordon

PLoS One· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensitivity to Change and Patient-Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Data-Driven Analysis.
Florian Krismer, Klaus Seppi, Linus Jönsson, Daniel Oudin Åström, Anna-Karin Berger, Mark Forrest Gordon

Mov Disord· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database.
Catherine B Johannes, Catherine W Saltus, James A Kaye, Brian Calingaert, Sigal Kaplan, Mark Forrest Gordon

Pharmacoepidemiol Drug Saf· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine.
Robert A Hauser, Hadas Barkay, Amanda Wilhelm, Maria Wieman, Juha-Matti Savola, Mark Forrest Gordon

Parkinsonism Relat Disord· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia.
Martha Sajatovic, Stacy Finkbeiner, Amanda Wilhelm, Hadas Barkay, Nayla Chaijale, Mark Forrest Gordon

Am J Geriatr Psychiatry· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.
Robert A Hauser, Hadas Barkay, Hubert H Fernandez, Stewart A Factor, Joohi Jimenez-Shahed, Mark Forrest Gordon

Front Neurol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial.
Joseph Jankovic, Barbara Coffey, Daniel O Claassen, Joohi Jimenez-Shahed, Barry J Gertz, Mark Forrest Gordon

JAMA Netw Open· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial.
Barbara Coffey, Joseph Jankovic, Daniel O Claassen, Joohi Jimenez-Shahed, Barry J Gertz, Mark Forrest Gordon

JAMA Netw Open· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On crushing of deutetrabenazine tablets.
Helena Knebel, Jessica Alexander, Amanda Wilhelm, Pippa Loupe, Frank Schneider, Mark Forrest Gordon

Am J Health Syst Pharm· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect.
Frank Schneider, David Stamler, Margaret Bradbury, Pippa S Loupe, Edward Hellriegel, Mark Forrest Gordon

Clin Pharmacol Drug Dev· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular and metabolic risk factor differences prior to dementia diagnosis: a multidatabase case-control study using European electronic health records.
Gayan Perera, P R Rijnbeek, Myriam Alexander, David Ansell, Paul Avillach, Mark Forrest Gordon

BMJ Open· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis